Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission. Chief Executive Officer Sean Nolan said the company dosed 17 patients in the over-enrolled REVEAL pivotal trial and four patients ages [...]
Taysha Gene Therapies Q2 Earnings Call Highlights
